Current Report Filing (8-k)
November 09 2017 - 4:06PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C.
20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
November 9, 2017
Date
of
Report
(Date
of
earliest
event
reported)
HELIUS MEDICAL TECHNOLOGIES, INC.
(Exact name of registrant as specified in its charter)
WYOMING
|
000-55364
|
36-4787690
|
(State or other jurisdiction of
|
(Commission
|
(I.R.S. Employer
|
incorporation or organization)
|
File Number)
|
Identification No.)
|
(Exact name
of
registrant as
specified
in
charter)
642 Newtown Yardley Road Suite 100
Newtown, Pennsylvania, 18940
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (215) 944-6100
Check
the
appropriate
box
below
if
the
Form
8-K
filing
is
intended
to
simultaneously
satisfy
the
filing
obligation
of
the
registrant
under
any
of
the
following
provisions:
|
☐
|
Written
communications
pursuant
to
Rule
425
under
the
Securities
Act
(17
CFR
230.425)
|
|
☐
|
Soliciting
material
pursuant
to
Rule
14a12
under
the
Exchange
Act
(17
CFR
240.14a12)
|
|
☐
|
Precommencement
communications
pursuant
to
Rule
14d2(b)
under
the
Exchange
Act
(17
CFR
240.14d2(b))
|
|
☐
|
Precommencement
communications
pursuant
to
Rule
13e4(c)
under
the
Exchange
Act
(17
CFR
240.13e4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b‑2 of the Securities Exchange Act of 1934 (§240.12b‑2 of this chapter).
Emerging growth company
☑
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act
☑
1
Item 7.01
|
Regulation FD Disclosure
|
On November 9, 2017, Helius Medical Technologies, Inc. (the “Company”) hosted a live webcast to report on data from the Company’s completed registrational clinical trial of the PoNS™ device for the treatment of chronic balance deficits due to mild to moderate traumatic brain injury and a recently completed long term treatment study conducted at the University of Wisconsin-Madison (the “Data”). A copy of the slides presented during the webcast is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. A transcript of the webcast is being furnished as Exhibit 99.2 to this Current Report on Form 8-K. On November 9, 2017, the Company issued a press release announcing the Data. The full text of the Company’s press release is furnished as Exhibit 99.3 to this Current Report on Form 8-K.
The information in this Item 7.01 of this Current Report on Form 8-K (including Exhibits 99.1, 99.2 and 99.3) is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific references in such a filing.
Item 9.01.
Financial Statements and Exhibits.
(d) Exhibits
2
SIGNATURE
Pursuant
to
the
requirements
of
the
Securities
Exchange
Act
of
1934,
the
registrant
has
duly
caused this report to be signed on its behalf by the undersigned hereunto duly authorized
.
|
HELIUS MEDICAL TECHNOLOGIES, INC.
|
|
|
|
Dated: November 9, 2017
|
By:
|
/s/ Joyce LaViscount
|
|
|
Joyce LaViscount, Chief Financial Officer
|
|
|
3
Helius Medical Technolog... (NASDAQ:HSDT)
Historical Stock Chart
From Apr 2024 to May 2024
Helius Medical Technolog... (NASDAQ:HSDT)
Historical Stock Chart
From May 2023 to May 2024